WordNet

the 2nd letter of the Roman alphabet (同)b
the blood group whose red cells carry the B antigen (同)type_B, group B
of or relating to recombinant DNA
a cell or organism in which genetic recombination has occurred
immunogen consisting of a suspension of weakened or dead pathogenic cells injected in order to stimulate the production of antibodies (同)vaccinum
accumulate (liquids or gases) on the surface
inflammation of the liver caused by a virus or a toxin

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. B型肝炎ウイルスワクチン hepatitis b virus vaccination
2. HIV感染成人におけるB型肝炎ウイルス感染の予防 prevention of hepatitis b virus infection in the hiv infected adult
3. A型肝炎ウイルスワクチンと曝露後の予防 hepatitis a virus vaccination and postexposure prophylaxis
4. 肝炎ウイルスと新生児：臨床症状および治療 hepatitis viruses and the newborn clinical manifestations and treatment
5. 慢性肝疾患患者のための予防接種 immunizations for patients with chronic liver disease

The structure of HBsAg particles is not modified upon their adsorption on aluminium hydroxide gel.

Greiner VJ1, Ronzon F, Larquet E, Desbat B, Estèves C, Bonvin J, Gréco F, Manin C, Klymchenko AS, Mély Y.
Vaccine.Vaccine.2012 Jul 27;30(35):5240-5. doi: 10.1016/j.vaccine.2012.05.082. Epub 2012 Jun 15.
Current Hepatitis B vaccines are based on recombinant Hepatitis B surface antigen (HBsAg) virus-like particles adsorbed on aluminium (Al) gel. These particles exhibit a lipoprotein-like structure with about 70 protein S molecules in association with various types of lipids. To determine whether the
PMID 22705175

Comparison of humoral and cell-mediated immune responses to cationic PLGA microspheres containing recombinant hepatitis B antigen.

Saini V1, Jain V, Sudheesh MS, Jaganathan KS, Murthy PK, Kohli DV.
International journal of pharmaceutics.Int J Pharm.2011 Apr 15;408(1-2):50-7. doi: 10.1016/j.ijpharm.2011.01.045. Epub 2011 Feb 1.
Presently available marketed alum adsorbed hepatitis B vaccine used for prophylactic immunization, can effectively elicit humoral immunity but is poor inducer of cell-mediated immunity (CMI). Besides, conventional alum-adjuvant vaccines require multiple injections to achieve long-lasting protective
PMID 21291968

Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial.

Zhu FC1, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Wang H, Yang CL, Jiang HM, Cai JP, Wang YJ, Ai X, Hu YM, Tang Q, Yao X, Yan Q, Xian YL, Wu T, Li YM, Miao J, Ng MH, Shih JW, Xia NS.
Lancet (London, England).Lancet.2010 Sep 11;376(9744):895-902. doi: 10.1016/S0140-6736(10)61030-6. Epub 2010 Aug 20.
BACKGROUND: Seroprevalence data suggest that a third of the world's population has been infected with the hepatitis E virus. Our aim was to assess efficacy and safety of a recombinant hepatitis E vaccine, HEV 239 (Hecolin; Xiamen Innovax Biotech, Xiamen, China) in a randomised, double-blind, placebo
PMID 20728932